List of Regenacy Pharmaceuticals patents

List of Regenacy Pharmaceuticals patents

List of Bookham Technology patents

List of Epivax, Inc. patents

List of Clark Equipment Company patents

List of funding rounds for Trustpilot

CEOs of plastics industry companies

Patents where

Current Assignee

Name

is

Regenacy Pharmaceuticals

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 9957259 Selective HDAC1 and HDAC2 inhibitors	Patent 9957259 was granted and assigned to Regenacy Pharmaceuticals on May, 2018 by the United States Patent and Trademark Office.	Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	9957259	May 1, 2018
	‌ US Patent 9765066 Selective HDAC1 and HDAC2 inhibitors	Patent 9765066 was granted and assigned to Regenacy Pharmaceuticals on September, 2017 by the United States Patent and Trademark Office.		Regenacy Pharmaceuticals		United States Patent and Trademark Office	9765066	September 19, 2017
	‌ US Patent 10040769 HDAC inhibitors for the treatment of diabetic peripheral neuropathy	Patent 10040769 was granted and assigned to Regenacy Pharmaceuticals on August, 2018 by the United States Patent and Trademark Office.		Regenacy Pharmaceuticals		United States Patent and Trademark Office	10040769	August 7, 2018
	‌ US Patent 10358421 Piperidine derivatives as HDAC1/2 inhibitors	Patent 10358421 was granted and assigned to Regenacy Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.	Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	10358421	July 23, 2019
	‌ US Patent 9790180 Piperidine derivatives as HDAC1/2 inhibitors	Patent 9790180 was granted and assigned to Regenacy Pharmaceuticals on October, 2017 by the United States Patent and Trademark Office.		Regenacy Pharmaceuticals		United States Patent and Trademark Office	9790180	October 17, 2017
	‌ US Patent 10125131 Selective HDAC3 inhibitors	Patent 10125131 was granted and assigned to Regenacy Pharmaceuticals on November, 2018 by the United States Patent and Trademark Office.	Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	10125131	November 13, 2018
	‌ US Patent 10968180 Piperidine derivatives as HDAC1/2 inhibitors	Patent 10968180 was granted and assigned to Regenacy Pharmaceuticals on April, 2021 by the United States Patent and Trademark Office.	Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	10968180	April 6, 2021
	‌ US Patent 10385031 Substituted piperazines as selective HDAC1,2 inhibitors	Patent 10385031 was granted and assigned to Regenacy Pharmaceuticals on August, 2019 by the United States Patent and Trademark Office.	Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	10385031	August 20, 2019
	‌ US Patent 10858323 HDAC inhibitors for the treatment of diabetic peripheral neuropathy	Patent 10858323 was granted and assigned to Regenacy Pharmaceuticals on December, 2020 by the United States Patent and Trademark Office.	Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	10858323	December 8, 2020
	‌ US Patent 11542242 Substituted piperazines as selective HDAC1,2 inhibitors	Patent 11542242 was granted and assigned to Regenacy Pharmaceuticals on January, 2023 by the United States Patent and Trademark Office.	Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	11542242	January 3, 2023
	‌ US Patent 10239837 Piperidine derivatives as HDAC1/2 inhibitors	Patent 10239837 was granted and assigned to Regenacy Pharmaceuticals on March, 2019 by the United States Patent and Trademark Office.	Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	10239837	March 26, 2019
	‌ US Patent 10774056 Substituted piperazines as selective HDAC1,2 inhibitors	Patent 10774056 was granted and assigned to Regenacy Pharmaceuticals on September, 2020 by the United States Patent and Trademark Office.	Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	10774056	September 15, 2020
	‌ US Patent 11702389 Piperidine derivatives as HDAC1/2 inhibitors		Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	11702389	July 18, 2023
	‌ US Patent 11858919 HDAC1,2 inhibitors	Patent 11858919 was granted and assigned to Regenacy Pharmaceuticals on January, 2024 by the United States Patent and Trademark Office.	Regenacy Pharmaceuticals	Regenacy Pharmaceuticals		United States Patent and Trademark Office	11858919	January 2, 2024

14 results

0 selected

14 results

0 selected